调节性T细胞与肿瘤免疫  

Regulatory T cell and tumor immunity

作　　者：张元莉[1] 关泉林[1] 祝秉东[2] 

机构地区：[1]兰州大学第一医院肿瘤外科,甘肃730000 [2]兰州大学医学院结核病研究中心

出　　处：《国际肿瘤学杂志》2012年第1期8-11,共4页Journal of International Oncology

基　　金：基金项目：国家自然科学基金资助项目（81072499）

摘　　要：调节性T细胞（Treg）是一类有负调节作用的T细胞亚群，包括CD4’Treg、CD8’Treg、NKT Treg和DNTreg细胞等4大类，主要发挥抑制性免疫调节功能，是肿瘤免疫逃逸的重要因素。这些机制包括分泌多种免疫抑制性细胞因子、分泌颗粒酶和穿孔素杀伤效应细胞、竞争和抑制IL-2、通过T淋巴细胞毒性相关抗原（CTLA）-4影响Treg的分化和增殖等。以Treg及免疫抑制性分子作为靶点，清除Treg，控制Treg的数量和功能，增强机体对肿瘤的免疫应答，为肿瘤免疫治疗提供了新思路。Regulatory T cells （Treg） , a group of negative regulatory cells, have four subsets： CD4 ＋ Treg, CD8 ＋ Treg, NKT Treg and DN Treg cells. They play an essential role in the inhibitive immune-regulation and might be the key factors of neoplasms immune escape. These mechanisms include inhibiting the effector cell function by inhibitory cytokines, killing effector cells by granzyme and perforin, competition and inhibiting IL-2, and affecting Treg differentiation and proliferation by regulating the function of CTLA-4, etc. Tumor immunotherapies targeting Treg and related immunosuppressive factors, such as remove Trcg or controling the numbers and functions, enhances the immune response against tumors, which might offer a new method of tumor immunotherapy.

关 键 词：T淋巴细胞 调节性 肿瘤 免疫疗法 

分 类 号：R730.3[医药卫生—肿瘤]